Danaher Corporation (DHR) FY2025 10-K Annual Report
Danaher Corporation (DHR) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 24, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
Danaher Corporation FY2025 10-K Analysis
Business Overview
- • Global science/technology platform across Biotechnology, Life Sciences, and Diagnostics segments; high recurring-revenue model via consumables and direct sales in ~50 countries
- • ~60,000 employees (associates) as of Dec 31, 2025; ~22,000 in North America, ~20,000 Western Europe, ~15,000 high-growth markets
- • US geographic concentration notable: North America represents 41% of sales in the United States alone; high-growth markets (Eastern Europe, Middle East, Africa, Latin America, Asia ex-Japan/AU/NZ) flagged as key future growth driver
- • EU MDR/IVDR compliance deadlines extended to May 2026–Dec 2028 (MDR) and May 2026–May 2028 (IVDR), creating ongoing regulatory adaptation burden across Diagnostics and Life Sciences portfolios
- • Life Sciences segment anchors on 2023 Abcam acquisition (protein consumables/antibodies), the most recent portfolio addition, reinforcing proteomics and drug-discovery consumables as strategic build-out priority
Management Discussion & Analysis
- • Revenue $24.6B, up 3.0% YoY; core sales +2.0% driven by Biotechnology (+6.5% core) and Diagnostics (+1.5% core), offset by Life Sciences (-1.5% core)
- • Operating margin 19.1% vs 20.4%; gross margin 59.1% vs 59.5%; SG&A 33.5% vs 32.5% of sales, pressured by $533M impairment charges
- • Best segment: Biotechnology — sales $7.3B (+8.0%), operating margin 25.6% vs 24.9%; worst: Life Sciences — flat sales $7.3B, operating margin collapsed to 7.1% vs 12.0%
- • Operating cash flow $6.4B; capex $1.2B; share buybacks $3.1B; dividends $878M; net debt rose to ~$18.4B total debt vs $16.0B in 2024
- • 2026 outlook: Bioprocessing growth trend similar to 2025; Life Sciences modest improvement but below historical levels; Diagnostics higher growth as China headwinds ease; tariff costs <$300M in 2025 with ongoing uncertainty from trade policy shifts
Risk Factors
- • IEEPA tariff authority struck down by U.S. Supreme Court Feb 2026; administration pursuing new tariffs under alternative authority — full impact still uncertain
- • ~59% of 2025 sales from outside U.S.; China alone ~11% of sales, with government-mandated volume-based procurement programs actively suppressing prices
- • Sole/limited-source suppliers for key components; supply interruptions cannot be quickly remedied due to regulatory qualification requirements
- • $18.4B outstanding debt as of Dec 31, 2025; additional debt expected to finance pending Masimo Corporation acquisition
- • FDA staffing reductions risk delays to 510(k) clearances and inspection schedules across Danaher's regulated medical device product lines
Danaher Corporation FY2025 Key Financial MetricsXBRL
Revenue
$24.6B
▲ +2.9% YoY
Net Income
$3.6B
▼ -7.3% YoY
Gross Margin
59.1%
▼ -39bp YoY
Operating Margin
19.1%
▼ -128bp YoY
Net Margin
14.7%
▼ -162bp YoY
ROE
6.9%
▼ -99bp YoY
Total Assets
$83.5B
▲ +7.6% YoY
EPS (Diluted)
$5.05
▼ -4.5% YoY
Operating Cash Flow
$6.4B
▼ -4.1% YoY
Source: XBRL data from Danaher Corporation FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Danaher Corporation
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.